Синтез новых тиазоло[3,2-а]пиримидинов и in silico анализ их биоактивности

Разработан эффективный метод получения и синтезированы новые тиазоло[3,2-a]пиримидины, содержащие н-пентановый или β-гидроксициклопропановый, а также флуоресцирующий бензо[f]кумариновый заместители с выходами более 60 %. Компьютерными методами (in silico) показана способность полученных соединений проникать через липидный бислой и оценено их сродство к ряду протеинкиназ (соединения 4 и 6 связываются с протеинкиназой AKT1 с кодом PDB 3о96; величины, рассчитываемые программой Autodock Vina энергии связывания (E_bind), составили: -10,9 и -10,6 ккал/моль), ацетилхолинэстеразе и цитохромам P450 человека (для цитохрома P450 3A4, pdb 5vcd, E_bind -12,3 ккал/моль).

1. Recent synthetic and medicinal perspectives of dihydropyrimidinones: а review / R. Kaur [et al.] // Eur. J. Med. Chem. – 2017. – Vol. 132. – P. 108–134. https://doi.org/10.1016/j.ejmech.2017.03.025

2. One-pot synthesis of 1,2,3,4-tetrahydropyrimidin-2(1H)-thione derivatives and their biological activity / M. A. I. Salem [et al.] // J. Heterocyclic Chem.– 2016. – Vol. 53, N 2. – P. 545–557. https://doi.org/10.1002/jhet.2358

3. One-pot synthesis of thiazolo[3,2-a]pyrimidine derivatives, their cytotoxic evaluation and molecular docking studies / T. Sekhar [et al.] // Spectrochim. Acta A Mol. Biomol. Spectrosc. – 2020. – Vol. 231. – P. 118056. https://doi.org/10.1016/j.saa.2020.118056

4. Synthesis and antitumor activity of isolongifoleno[7,8-d]thiazolo[3,2-a]pyrimidine derivatives via enhancing ROS level / C. Ma [et al.] // Chem. Biol. Drug Des. – 2019. – Vol. 94. – P. 1457–1466. https://doi.org/10.1111/cbdd.13522

5. Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors / Y. Sun [et al.] // Bioorg. Med. Chem. – 2021. – Vol. 29. – P. 115890. https://doi.org/10.1016/j.bmc.2020.115890

6. Synthesis, crystal Ssructure, and biological evaluation of fused thiazolo[3,2-a]pyrimidines as new acetylcholinesterase inhibitors / M. Y. Mahgoub[et al.] // Molecules. – 2019. – Vol. 24, N 12. – P. 2306. https://doi.org/10.3390/molecules24122306

7. Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies / M. Murahari [et al.] // Eur. J. Med. Chem.– 2017. – Vol. 139. – P. 961–981. https://doi.org/10.1016/j.ejmech.2017.08.023

8. Acetylcholinesterase inhibitors: structure based design, synthesis, pharmacophore modeling and virtual screening / K. R. Valasani [et al.] // J. Chem. Inf. Mod. – 2013.– Vol. 53, N 8. – P. –2033–2046. https://doi.org/10.1021/ci400196z

9. Dihydropyrimidones: as novel class of β-glucuronidase inhibitors / F. Ali [et al.] // Bioorg. Med. Chem. – 2016. – Vol. 24, N 16. – P. 3624–3635. https://doi.org/10.1016/j.bmc.2016.06.002

10. Exploration of the dihydropyrimidine scaffold for the development of new potential anti-inflammatory agents blocking prostaglandin E2 synthase-1 enzyme (mPGES-1) / G. Lauroa [et al.] // Eur. J. Med. Chem. – 2014. – Vol. 80. – P. 407–415. https://doi.org/doi.org/10.1016/j.ejmech.2014.04.061

11. Identification of substituted [3, 2-a] pyrimidines as selective antiviral agents: Molecular modeling study / K. R. Babu [et al.] // Antiviral Research. – 2012. – Vol. 95, N 2. – P. 118–127. https://doi.org/doi.org/10.1016/j.antiviral.2012.05.010

12. Synthesis of dihydropyrimidine α, γ-diketobutanoic acid derivatives targeting HIV integrase / O. Sari [et al.] // Eur. J. Med. Chem. – 2015. – Vol. 104. – P. 127–138. https://doi.org/doi.org/10.1016/j.ejmech.2015.09.015

13. Synthesis, molecular docking, and cardioprotective activity of 2-methylthio-1,4-dihydropyrimidines / R. L. Sawant [et al.] // Med. Chem. Res. – 2012. – Vol. 21, N 8. – P. 1825–1832. https://doi.org/10.1007/s00044-011-9700-7

14. Discovery and development of thiazolo[3,2-a]pyrimidinone derivatives as general inhibitors of Bcl-2 family proteins / B. Zhou [et al.] // Chem. Med. Chem. – 2011. – Vol. 6, N 5. – P. 904–921. https://doi.org/10.1002/cmdc.201000484

15. Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors / S. Kolb [et al.] // Chem. Med. Chem. – 2009. – Vol. 4, N 4. – P .633–648. https://doi.org/10.1002/cmdc.200800415

16. A new insight into subinteractomes of functional antagonists: thromboxane (CYP5A1) and prostacyclin (CYP8A1) synthases / P. V. Ershov[et al.] // Cell Biol. Int. – 2021.– Vol. 45, N 6. – P.1175–1182. https://doi.org/10.1002/cbin.11564

17. От структуры и функции ферментов биосинтеза стероидов к новым генно-инженерным технологиям / Л. А. Новикова [и др.] // Успехи биол. химии. – 2009. – Т. 49.–P. 159–208.

18. Bioactivation of cyclopropyl rings by P450: an observation encountered during the optimisation of a series of hepatitis C virus NS5B inhibitors / X. Zhuo [et al.] // Xenobiotica. – 2018. – Vol. 48, N 12. – P. 1215–1226. https://doi.org/10.1080/00498254.2017.1409915

19. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents / R. S. Keri [et al.] // Eur. J. Med. Chem.– 2015. – Vol. 100. – P.257–269. https://doi.org/10.1016/j.ejmech.2015.06.017

20. Lomize, A. L. Anisotropic solvent model of the lipid bilayer. 2. Energetics of insertion of small molecules, peptides, and proteins in membranes / A. L. Lomize, I. D. Pogozheva, H. I. Mosberg// J. Chem. Inf. Mod. – 2011. – Vol. 51, N 4. – P.930–946. https://doi.org/doi 10.1021/ci200020k

21. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3, 2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor / C.-H. Jin[et al.] // Bioorg. Med. Chem. – 2014. – Vol. 22, N 17. – P. 4553–4565. https://doi.org/doi.org/10.1016/j.bmc.2014.07.037